Systems and methods for cardiac plexus neuromodulation
Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4/5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.
1. A method of modulating nerves of a cardiac plexus of a patient, comprising:
inserting a catheter percutaneously into a first blood vessel;
advancing the catheter into a second blood vessel;
penetrating a wall of the second blood vessel with a portion of the catheter, thereby accessing the cardiac plexus; and
modulating nerves within the cardiac plexus by delivering a gel comprising a therapeutic agent to contact at least a portion of the cardiac plexus.
2. The method of claim 1 , wherein the modulating comprises delivering the gel, wherein the gel is a hydrogel comprising a therapeutic agent to modulate nerves in the cardiac plexus.
3. The method of claim 2 , wherein the hydrogel comprises an in situ crosslinking hydrogel or an injectable hydrogel slurry.
4. The method of claim 1 , wherein the modulating comprises reducing the signs or symptoms of cardiac arrhythmias.
5. The method of claim 1 , wherein the cardiac arrhythmias comprise atrial fibrillation.
6. The method of claim 1 , wherein the modulating comprises reducing the signs or symptoms of one or more of congestive heart failure, cardiogenic pain, and coronary artery disease.
7. The method of claim 1 , wherein the gel comprises polyethylene glycol.